BIOSIMILARS MARKET Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017-2025 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Biosimilars Market Overview Biosimilars are biological medical products which are the identical copies of the original products. Biosimilars are also termed as subsequent entry biologic or follow-on biologic. Biosimilars are expected to possess active properties, similar to that of officially approved original product at present. Biosimilars can be manufactured only when the patent for the original innovator product expires. Biologics or biosimilars are sensitive to changes in manufacturing process due to the higher molecular complexity. In 2010, The Food and Drug Administration (FDA) has gained the authority to approve biosimilars as a part of Patient Protection and Affordable Care Act. The approval process is based on thorough demonstration of similarity and comparability with the existing approved product. Biosimilars are generally derived from living cells of plants, animals, yeast, bacteria and viruses, through genetic engineering processes including controlled gene expression and recombinant DNA technology. Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/750 Patent expiry of blockbuster drugs and increasing government initiatives for biosimilars promotion drives the growth of biosimilars market The key factors driving the growth of biosimilars market are the increasing demand due to their cost-effectiveness, rising geriatric population, growing pressure to curtail healthcare expenditure, increasing government support and initiatives to develop and promote biosimilars, strategic collaborations to enhance productivity and clinical trial activities for biosimilars. © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Diabetes medicine and oncology segments are expected to attain faster growth during the forecast period The global biosimilars market is segmented on the basis of product type, manufacturing type, application, end user and geography. • On the basis of product type, the global biosimilars market is segmented into: • Monoclonal Antibodies • Recombinant Hormones • Anti-Inflammatory Agents • Recombinant Growth Stimulators • Immunomodulators On the basis of by manufacturing type, the global biosimilars market is segmented into: • In-house Manufacturing • Contract Manufacturing Organizations Request a Customization: https://www.coherentmarketinsights.com/insight/request-customization/750 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Cost effective potential of biosimilars is the primary factor expected to boost the biosimilars market in Asia Pacific Regional segmentation of the biosimilars market by Coherent Market Insights comprises North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. The first FDA approval biosimilar in 2015, Sandoz’s Zarxio has marked a promising hit of the biosimilars market across North America. According to the American Society of Health-System Pharmacists survey in 2013, about 99% of 214 surveyed pharmacy directors reported at least one oncologic drug shortage with the consequences of adopting the distribution of biosimilars to meet the rising demands. Also, the demand for biosimilars is expected to gather momentum in North America owing to the rising prevalence of cancers, autoimmune diseases, kidney failures and growth hormone deficiency and increasing approval rates by FDA. The treatment for various diseases including diabetes, rheumatoid arthritis and types of cancers are anticipated to become affordable in developing countries like China and India, thus providing opportunities for major players in the Asia Pacific biosimilar market to expand during the forecast period. Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/750 The increase in product extensions integrated with technological innovations is expected to intensify the competitive environment within manufacturers Key players operating in the biosimilars market include Sandoz International GmbH, Apotex, Biocon, Zydus Cadila Healthcare, Celltrion and Pfizer. The leading manufacturers are focusing on outsourcing the production of biosimilar products with strategic collaborations to replace the existing expensive drugs. For instance, in August 2016, the FDA approval by Sandoz for the biosimilar Erelzi, used for treating multiple inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis and juvenile idiopathic arthritis. © Coherent market Insights. All Rights Reserved ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES INDUSTRY ANALYSIS CUSTOMIZED RESEARCH SYNDICATED RESEARCH MARKET INTELLIGENCE SERVICES CONSULT STUDIES COUNTRY SPECIFIC STUDIES © Coherent market Insights. All Rights Reserved ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators Private and Government organization Distributors, Retailors and Value Added Resellers Outsourcing Companies Healthcare IT Solutions Developers Universities and Business Schools. © Coherent market Insights. All Rights Reserved KEY STATS RESEARCH SOLUTIONS 100+ FEASIBILITY STUDIES Insights Published Per Year GLOBAL REPORTS 150+ Consulting Projects Till Date COUNTRY ANALYSIS CONSULT PROJECTS 125+ Clients Worldwide Per Year 110+ SURVEY RESEARCH EXCEL FORECAST DATABASE CUSTOMIZED SOLUTIONS COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: [email protected] For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights [email protected] +1-206-701-6702 © Coherent market Insights. All Rights Reserved
Biosimilars are biological medical products which are the identical copies of the original products. Biosimilars are also termed as subsequent entry biologic or follow-on biologic. Biosimilars are expected to possess active properties, similar to that of officially approved original product at present. Biosimilars can be manufactured only when the patent for the original innovator product expires. Biologics or biosimilars are sensitive to changes in manufacturing process due to the higher molecular complexity. In 2010, The Food and Drug Administration (FDA) has gained the authority to approve biosimilars as a part of Patient Protection and Affordable Care Act. The approval process is based on thorough demonstration of similarity and comparability with the existing approved product. Biosimilars are generally derived from living cells of plants, animals, yeast, bacteria and viruses, through genetic engineering processes including controlled gene expression and recombinant DNA technology. Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/750
© Copyright 2024 Paperzz